Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures

Publications

COPD_pub_new

COPD

Singer M, Martin LD, Vargaftig BB, Park J, Gruber AD, Li Y, Adler KB.  A MARCKS-related peptide blocks mucus hypersecretion in a murine model of asthma.  Nature Medicine 10:193-196; 2004.

PMID: 14716307
DOI: 10.1038/nm983

Park J-A, Adler KB: Potential therapy for mucus hypersecretion in COPD. Journal of  Organ Dysfunction 3: 66-71, 2007.

Agrawal A, Rengarajan S, Adler KB, Ram A, Ghosh B, Fahim M, Dickey BF: Inhibition of mucin secretion with MARCKS-related peptide improves airflow obstruction in a mouse model of asthma. Journal of  Applied  Physiology 102:399-405, 2007.

PMID: 16946028
DOI: 10.1152/japplphysiol.00630.2006

Agrawal A,  Murphy EC III, Park J,  Adler KB, Parikh I: Aerosolized BIO-11006, a novel MARCKS-related peptide, improves airway obstruction in a mouse model of mucus hypersecretion.  Journal of Epithelial Biology and Pharmacology 3: 13-20, 2011.  

Scientific Presentations:

Yin Q, Lampe WR, Fang S, Crews A, Yin J, Adler KB: Enhanced Expression of Myristoylated Alanine – Rich C Kinase Substrate (MARCKS) in Airway Epithelium of an Animal Model of Allergic Airway Inflammation and Human Patients with COPD.  American Journal of Respiratory and  Critical  Care Medicine 185:A1281, 2012. Presented at American Thoracic Society Annual Meeting, San Francisco, CA, May 2012.

ARDS-pub

ARDS

Yin Q*, Fang S*,  Park J, Crews A, Parikh I, Adler KB: An Inhaled Inhibitor of MARCKS Reverses LPS-induced Acute Lung Injury in Mice”. (* Co – first authors) American Journal of Respiratory Cell and Molecular Biology 55: 617-622, 2016.  

PMID: 27556883
PMCID: PMC5105187
DOI: 10.1165/rcmb.2016-0236RC

Sheats MK, Yin Q, Fang S, Crews AL, Adler KB: MARCKS protein and Lung Disease.  American Journal of Respiratory Cell and Molecular Biology 60:16-27, 2019. 

PMID: 30339463
PMCID: PMC6348718
DOI: 10.1165/rcmb.2018-0285TR

Scientific Presentations:

Yin Q, Fang S, Park J, Crews AL, Adler KB: LPS-induced acute lung injury in mice is reversed by inhalation of aerosolized peptides that inhibit function of MARCKS protein.  American Journal of Respiratory and Critical Care Medicine 189; A5329, 2014. Presented at American Thoracic Society Annual Meeting, San Diego, CA, May 2014

Dickson B, Parikh I, Adler KB: A Placebo-Controlled Clinical Study of a MARCKS Inhibitory Peptide in the Treatment of Established ARDS. Presented at 5th International ARDS Conference, Berlin, Germany, June 2019.

Cancer

Cancer

Chen CS, Thai P, Yoneda K,  Adler KB, Yang P-C, Wu R: A peptide that inhibits function of Myristoylated Alanine – Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene 33:3696–3706, 2014.

PMID: 23955080
PMCID: PMC4631387
DOI: 10.1038/onc.2013.336

Chen CS, Chiu CL, Adler KB, Wu R: A novel predictor of cancer malignancy and potential therapeutic target: Up-regulation of MARCKS phosphorylation in lung cancer. American Journal of Respiratory and Critical Care Medicine 189, 1002-1004, 2014.

PMID: 24735036
PMCID: PMC4098099
DOI: 10.1164/rccm.201401-0053LE

Sheats MK, Yin Q, Fang S, Crews AL, Adler KB: MARCKS protein and Lung Disease.  American Journal of Respiratory Cell and Molecular Biology 60:16-27, 2019. 

PMID: 30339463
PMCID: PMC6348718
DOI: 10.1165/rcmb.2018-0285TR

Scientific presentations:

Park J, Fang S, Yin Q, Crews AL, Adler KB: MARCKS binding to membrane phosphoinositide bisphosphate (PIP2) is involved in migration of lung cancer cells.  American Journal of Respiratory and Critical Care Medicine 89; A5410, 2014. Presented at American Thoracic Society Annual Meeting, San Diego, CA, May 2014

Yin Q, Crews A, Fang S, Park J,  Parikh I,  Long W,  Chen CH,  Wu R,  Adler KB:  Inhibition of lung cancer metastasis in mice by inhaled aerosolized anti-MARCKS peptides.   American Journal of Respiratory and Critical Care Medicine 191; A2429, 2015. Presented at American Thoracic Society Annual Meeting, Denver, CO, May 2015.

Fang S, Yin Q, Park J, Crews A, Dickson B, Adler KB: Synergy between anti-MARCKS peptides and chemotherapeutic agents in attenuation of NSCLC metastasis and tumor growth could be based on MARCKS cell cycle regulation. American Journal of Respiratory and Critical Care Medicine  193; A3131, 2016. Presented at American Thoracic Society Annual Meeting, San Francisco, CA, May 2016.

Park J, Fang S, Yin Q,  Crews AL,  Adler KB: Modulation of FAK activity by MARCKS is involved in migration of lung cancer cells. American Journal of Respiratory and Critical Care Medicine  193 A2365, 2016. Presented at American Thoracic Society Annual Meeting, San Francisco, CA, May 2016

Yin Q, Fang S, Park J, Crews A, Parikh I, Dickson B, Adler KB: MARCKS-inhibitory peptides synergize with cisplatin to inhibit metastasis and primary tumor growth in mouse orthotopic lung cancer models. American Journal of Respiratory and Critical Care Medicine 193, A3135, 2016.  Presented at American Thoracic Society Annual Meeting, San Francisco, CA, May 2016

Yin Q, Fang S, JJ Park JJ, AL Crews AL, Dickson B, Parikh I, Adler KB: An inhibitor of MARCKS Protein Attenuates Migration of Human Lung Cancer cells; role of Protein Phosphatase Type 2A (PP2A) American Journal of Respiratory and Critical Care Medicine 195, A2357, 2017. Presented at American Thoracic Society Annual Meeting, Washington, DC, May 2017

Fang S, Yin Q, Park JJ, Crews AL, Dickson B, Adler KB: A Peptide Inhibitor of MARCKS Protein Attenuates Migration of Human Lung Cancer Cells; Cytoskeletal Rearrangement upon Treatment Indicates a Shift from Motile to Structural Cells.  American Journal of Respiratory and Critical Care Medicine 195:A2358, 2017. Presented at American Thoracic Society Annual Meeting, Washington, DC, May 2017,

Adler KB, Dickson B: An inhaled MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) -inhibitory drug, BIO-11006, elicited a statistically-significant result (p= 0.02) in Overall Response Rate (ORR) after 3 months compared to Standard of Care chemotherapy in a phase 2 trial of late stage Non Small Cell Lung Cancer (NSCLC). American J Resp Crit Care Med, In Press, 2020. To be presented at American Thoracic Society Annual Meeting, Philadelphia, PA (Meeting canceled due to COVID-19).